S
Superluminal Medicines
Generative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created
About Superluminal Medicines
Superluminal Medicines operates at the intersection of deep biology, chemistry, and machine learning to revolutionize drug discovery. The company focuses on creating candidate-ready compounds with unprecedented speed and accuracy. By leveraging a proprietary big data infrastructure and advanced predictive design models, Superluminal Medicines accurately models protein shapes and designs highly selective compounds to target precise structural changes for therapeutic effects. The company primarily serves pharmaceutical and biotech firms looking to accelerate their drug discovery processes. Operating in the highly competitive pharmaceutical market, Superluminal Medicines employs a business model centered around partnerships and collaborations, generating revenue through licensing agreements and milestone-based payments. The recent $33 million seed round underscores investor confidence in their innovative approach and potential for significant impact in the field of small molecule therapeutics.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Boston, United States
- Employees
- 51
- Open positions
- 9
- Dealroom signal
- 93.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Biotech and Pharma, Novel AI, Generative AI, AI Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2024 | $120M | $480M | Gaingels · Cooley · Eli Lilly · Insight Partners | ↗ |
| SEEDOther financing | Aug 2023 | $33M | $132M | Insight Partners · Gaingels · RA Capital Management · NVentures | ↗ |
Growth signals
Latest recorded traffic for Superluminal Medicines is 5K monthly website visits, up 22% over the last three months. Superluminal Medicines's team grew 410% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
RA Capital Management
Insight Partners
Gaingels
NVentures
Series A3 investors entered at this stage
Cooley
Eli Lilly
Catalio Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Superluminal Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Superluminal Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.